Allarity Therapeutics announced the appointment of Alexander Epshinsky as its new Chief Financial Officer, effective September 12, 2024, following Joan Y. Brown's resignation. Epshinsky, a CPA with extensive experience in pharmaceutical and biotech companies, will receive a $340,000 annual base salary, RSUs worth $160,000, and a $50,000 signing bonus.The company has amended its At-The-Market Issuance Sales Agreement with Ascendiant Capital Markets, increasing the placement shares amount to $50 million. This modification comes as the company plans to resume its financing initiatives after a two-month pause to support its strategic goals and growth plans.Under Epshinsky's employment agreement, he is eligible for an annual bonus of up to 30% of base salary starting 2025, with prorated bonus for 2024. The agreement includes severance provisions of six months' salary for termination without cause or following a change of control.

Allarity Therapeutics announced the appointment of Alexander Epshinsky as its new Chief Financial Officer, effective September 12, 2024, following Joan Y. Brown's resignation. Epshinsky, a CPA with extensive experience in pharmaceutical and biotech companies, will receive a $340,000 annual base salary, RSUs worth $160,000, and a $50,000 signing bonus.The company has amended its At-The-Market Issuance Sales Agreement with Ascendiant Capital Markets, increasing the placement shares amount to $50 million. This modification comes as the company plans to resume its financing initiatives after a two-month pause to support its strategic goals and growth plans.Under Epshinsky's employment agreement, he is eligible for an annual bonus of up to 30% of base salary starting 2025, with prorated bonus for 2024. The agreement includes severance provisions of six months' salary for termination without cause or following a change of control.